CalciMedica, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net (loss) income | $(5,042) | $130 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 549 | 414 |
| Depreciation | 15 | 15 |
| Change in the fair value of warrant liability | (1,377) | (5,590) |
| Change in the fair value of promissory note | (323) | — |
| Debt issuance costs | 334 | — |
| Transaction costs associated with warrants | — | 776 |
| Accretion of discount on short-term investments | (106) | (163) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current and non-current assets | 403 | (537) |
| Accounts payable | (87) | 129 |
| Accrued expenses and other liabilities | 756 | 111 |
| Net cash used in operating activities | (4,878) | (4,715) |
| Investing activities: | ||
| Purchase of investments | (6,634) | (17,853) |
| Maturity of investments | 5,400 | 4,750 |
| Purchase of property and equipment | (9) | — |
| Net cash used in investing activities | (1,243) | (13,103) |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 8 | 19,043 |
| Proceeds from issuance of promissory note payable, net | 9,766 | — |
| Proceeds from issuance of common stock from ATM Facility, net of issuance costs | 968 | — |
| Net cash provided by financing activities | 10,742 | 19,043 |
| Net increase in cash and cash equivalents | 4,621 | 1,225 |
| Cash and cash equivalents at beginning of period | 7,935 | 5,530 |
| Cash and cash equivalents at end of period | $12,556 | $6,755 |
| Supplemental cash flow information: | ||
| Fixed asset purchases in accounts payable | $5 | $— |
| Financing costs included in accounts payable and accrued expenses | $100 | $64 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.